| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Radhashree Maitra, Raviraja Seetharam, Lydia Tesfa, Titto A Augustine, Lidija Klampfer, Matthew C Coffey, John M Mariadason, Sanjay Goe. Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan. Oncotarget. vol 5. issue 9. 2015-02-19. PMID:24798549. |
reovirus preferentially induced apoptosis in kras mutant hct116 cells compared to its isogenic kras wt derivative, and in kras mutant iec cells. |
2015-02-19 |
2023-08-13 |
human |
| Radhashree Maitra, Raviraja Seetharam, Lydia Tesfa, Titto A Augustine, Lidija Klampfer, Matthew C Coffey, John M Mariadason, Sanjay Goe. Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan. Oncotarget. vol 5. issue 9. 2015-02-19. PMID:24798549. |
reovirus preferentially induces apoptosis in kras mutant colon cancer cells. |
2015-02-19 |
2023-08-13 |
human |
| Maged Zeineldin, Matthew A Miller, Ruth Sullivan, Kristi L Neufel. Nuclear adenomatous polyposis coli suppresses colitis-associated tumorigenesis in mice. Carcinogenesis. vol 35. issue 8. 2015-02-18. PMID:24894865. |
the aom-dss-induced colon adenoma histopathology, proliferation, apoptosis, stem cell number and β-catenin and kras mutation spectra were similar in apc(mnls/mnls) and apc(+/+) mice. |
2015-02-18 |
2023-08-13 |
mouse |
| Wen Xue, James E Dahlman, Tuomas Tammela, Omar F Khan, Sabina Sood, Apeksha Dave, Wenxin Cai, Leilani M Chirino, Gillian R Yang, Roderick Bronson, Denise G Crowley, Gaurav Sahay, Avi Schroeder, Robert Langer, Daniel G Anderson, Tyler Jack. Small RNA combination therapy for lung cancer. Proceedings of the National Academy of Sciences of the United States of America. vol 111. issue 34. 2014-11-25. PMID:25114235. |
the delivery of sirnas targeting kras reduced kras gene expression and mapk signaling, increased apoptosis, and inhibited tumor growth. |
2014-11-25 |
2023-08-13 |
mouse |
| Toshiyuki Tsunoda, Shuhei Ishikura, Keiko Doi, Hiroshi Matsuzaki, Yuri Iwaihara, Senji Shirasaw. Resveratrol induces luminal apoptosis of human colorectal cancer HCT116 cells in three-dimensional culture. Anticancer research. vol 34. issue 8. 2014-11-11. PMID:25075098. |
we have previously reported the crucial roles of oncogenic kirsten rat sarcoma viral oncogene homolog (kras) in inhibiting apoptosis and disrupting cell polarity via the regulation of phosphodiesterase 4 (pde4) expression in human colorectal cancer hct116 cells in three-dimensional cultures (3dc). |
2014-11-11 |
2023-08-13 |
human |
| Linjuan Zeng, Jingguo Li, Yong Wang, Chenchen Qian, Yinting Chen, Qiubo Zhang, Wei Wu, Zhong Lin, Jianzhong Liang, Xintao Shuai, Kaihong Huan. Combination of siRNA-directed Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic cancer. Nanomedicine : nanotechnology, biology, and medicine. vol 10. issue 2. 2014-09-04. PMID:24028894. |
combination of sirna-directed kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic cancer. |
2014-09-04 |
2023-08-12 |
human |
| Linjuan Zeng, Jingguo Li, Yong Wang, Chenchen Qian, Yinting Chen, Qiubo Zhang, Wei Wu, Zhong Lin, Jianzhong Liang, Xintao Shuai, Kaihong Huan. Combination of siRNA-directed Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic cancer. Nanomedicine : nanotechnology, biology, and medicine. vol 10. issue 2. 2014-09-04. PMID:24028894. |
consequently, co-administration of the two nanomedicines encapsulating sirna or arsenic showed ideal tumor growth inhibition both in vitro and in vivo as a result of synergistic effect of the sirna-directed kras oncogene silencing and arsenic-induced cell apoptosis. |
2014-09-04 |
2023-08-12 |
human |
| Hua Zhong, Cesar Sanchez, Dirk Spitzer, Dirk Spitrzer, Stacy Plambeck-Suess, Jesse Gibbs, Williams G Hawkins, David Denardo, Feng Gao, Robert A Pufahl, Albert C Lockhart, Mai Xu, David Linehan, Jason Weber, Andrea Wang-Gilla. Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models. PloS one. vol 8. issue 10. 2014-06-11. PMID:24130864. |
while bxpc-3 (kras wild type) and mia paca-2 (kras mutated) cell lines were sensitive to gdc0941 and azd6244 as single agents, synergistic inhibition of tumor cell growth and induction of apoptosis were observed in both cell lines when the two drugs were combined. |
2014-06-11 |
2023-08-12 |
Not clear |
| Jatin Roper, Mark J Sinnamon, Erin M Coffee, Peter Belmont, Lily Keung, Larissa Georgeon-Richard, Wei Vivian Wang, Anthony C Faber, Jihye Yun, Ömer H Yilmaz, Roderick T Bronson, Eric S Martin, Philip N Tsichlis, Kenneth E Hun. Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer. Cancer letters. vol 347. issue 2. 2014-06-02. PMID:24576621. |
combination pi3k/mek inhibition promotes tumor apoptosis and regression in pik3ca wild-type, kras mutant colorectal cancer. |
2014-06-02 |
2023-08-12 |
mouse |
| Xiang-Hua Zhang, Ying Cheng, Jung-Young Shin, Jeong-Oh Kim, Ji-Eun Oh, Jin-Hyoung Kan. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS. Cancer biology & therapy. vol 14. issue 7. 2014-05-01. PMID:23792647. |
combined cink4 and paclitaxel produced synergistic anti-proliferative activity and increased apoptosis through reduced cyclin d1 and bcl-2 in kras mutation-positive cancer cells. |
2014-05-01 |
2023-08-12 |
Not clear |
| Carles Barceló, Noelia Paco, Mireia Morell, Blanca Alvarez-Moya, Neus Bota-Rabassedas, Montserrat Jaumot, Felip Vilardell, Gabriel Capella, Neus Agel. Phosphorylation at Ser-181 of oncogenic KRAS is required for tumor growth. Cancer research. vol 74. issue 4. 2014-04-22. PMID:24371225. |
reduced growth of tumors composed of cells expressing the nonphosphorylatable kras s181a mutant was correlated with increased apoptosis. |
2014-04-22 |
2023-08-12 |
mouse |
| Tian Ma, Fabrizio Galimberti, Cherie P Erkmen, Vincent Memoli, Fadzai Chinyengetere, Lorenzo Sempere, Jan H Beumer, Bean N Anyang, William Nugent, David Johnstone, Gregory J Tsongalis, Jonathan M Kurie, Hua Li, James Direnzo, Yongli Guo, Sarah J Freemantle, Konstantin H Dragnev, Ethan Dmitrovsk. Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer. Molecular cancer therapeutics. vol 12. issue 8. 2014-04-01. PMID:23686769. |
in human (hop62, h522, and h23) and murine transgenic (ed-1, ed-2, lkr-13, and 393p, driven, respectively, by cyclin e, degradation-resistant cyclin e, kras, or kras/p53) lung cancer cell lines, vorinostat reduced growth, cyclin d1, and cyclin e levels, but induced p27, histone acetylation, and apoptosis. |
2014-04-01 |
2023-08-12 |
mouse |
| J Chen, H Bi, J Hou, X Zhang, C Zhang, L Yue, X Wen, D Liu, H Shi, J Yuan, J Liu, B Li. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells. Cell death & disease. vol 4. 2014-03-12. PMID:24071646. |
atorvastatin (1 μm) plus gefitinib treatment inhibited proliferation, promoted cell apoptosis, and reduced the akt activity in kras mutant nsclc cells compared with gefitinib alone. |
2014-03-12 |
2023-08-12 |
human |
| Areumnuri Kim, Jung-Eun Lee, Seung-Sook Lee, Cherin Kim, Sun-Joo Lee, Won-Suk Jang, Sunhoo Par. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer. International journal of cancer. vol 133. issue 4. 2013-08-12. PMID:23475782. |
suppression of pi3k/mtor by bez235 results in a growth inhibitory effect and enhanced apoptosis via bim activation in kras mutant cells. |
2013-08-12 |
2023-08-12 |
Not clear |
| Areumnuri Kim, Jung-Eun Lee, Seung-Sook Lee, Cherin Kim, Sun-Joo Lee, Won-Suk Jang, Sunhoo Par. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer. International journal of cancer. vol 133. issue 4. 2013-08-12. PMID:23475782. |
taken together, our data suggest that targeting pi3k/mtor sensitizes cells to apoptosis, implying that activation of pi3k/mtor signaling via kras or pik3ca mutation is an important pathway in crc cell growth. |
2013-08-12 |
2023-08-12 |
Not clear |
| Areumnuri Kim, Jung-Eun Lee, Seung-Sook Lee, Cherin Kim, Sun-Joo Lee, Won-Suk Jang, Sunhoo Par. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer. International journal of cancer. vol 133. issue 4. 2013-08-12. PMID:23475782. |
based on these results, coexistent kras and pik3ca mutations confer resistance to bez235 via suppression of bim-induced apoptosis, suggesting that combined treatment with conventional chemoagents is a potential strategy in the clinic. |
2013-08-12 |
2023-08-12 |
Not clear |
| Arup R Chakraborty, Robert W Robey, Victoria L Luchenko, Zhirong Zhan, Richard L Piekarz, Jean-Pierre Gillet, Andrew V Kossenkov, Julia Wilkerson, Louise C Showe, Michael M Gottesman, Nathan L Collie, Susan E Bate. MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor. Blood. vol 121. issue 20. 2013-08-05. PMID:23532732. |
romidepsin combined with mek inhibitors yielded greater apoptosis in cells expressing mutant kras compared with romidepsin treatment alone. |
2013-08-05 |
2023-08-12 |
Not clear |
| Qian Wu, Chao Wang, Li Guo, Qinyu Ge, Zuhong L. Identification and characterization of novel microRNA candidates from deep sequencing. Clinica chimica acta; international journal of clinical chemistry. vol 415. 2013-05-31. PMID:23153516. |
7 genes (cul3, kras, ets1, mnt, cntn3, ccnk and foxo3) which have a high prediction score and are associated with cell proliferation, apoptosis and cell cycle were chosen. |
2013-05-31 |
2023-08-12 |
mouse |
| Ryan B Corcoran, Katherine A Cheng, Aaron N Hata, Anthony C Faber, Hiromichi Ebi, Erin M Coffee, Patricia Greninger, Ronald D Brown, Jason T Godfrey, Travis J Cohoon, Youngchul Song, Eugene Lifshits, Kenneth E Hung, Toshi Shioda, Dora Dias-Santagata, Anurag Singh, Jeffrey Settleman, Cyril H Benes, Mari Mino-Kenudson, Kwok-Kin Wong, Jeffrey A Engelma. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer cell. vol 23. issue 1. 2013-03-26. PMID:23245996. |
abt-263 (navitoclax), a chemical inhibitor that blocks the ability of bcl-xl to bind and inhibit pro-apoptotic proteins, in combination with a mek inhibitor led to dramatic apoptosis in many kras mutant cell lines from different tissue types. |
2013-03-26 |
2023-08-12 |
mouse |
| Stéphane Pédeboscq, Denis Gravier, Françoise Casadebaig, Geneviève Hou, Arnaud Gissot, Christophe Rey, François Ichas, Francesca De Giorgi, Lydia Lartigue, Jean-Paul Pometa. Synthesis and evaluation of apoptosis induction of thienopyrimidine compounds on KRAS and BRAF mutated colorectal cancer cell lines. Bioorganic & medicinal chemistry. vol 20. issue 22. 2013-03-19. PMID:23063521. |
synthesis and evaluation of apoptosis induction of thienopyrimidine compounds on kras and braf mutated colorectal cancer cell lines. |
2013-03-19 |
2023-08-12 |
Not clear |